EMA committee adopts negative opinion on Eisai & Biogen's MAA for lecanemab for early Alzheimer's disease
Eisai Co., Ltd. and Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble …